Introduction. Fibromyalgia syndrome (FMS) is a pain disorder with an estimated prevalence
of 1–5%. It is associated with a variety of somatic and psychological disorders. Its exact …

There have been substantial advances in the pharmacotherapy of fibromyalgia (FM), which
have occurred in parallel with advances in our understanding of the pathophysiology of FM …

Introduction: Fibromyalgia is a syndrome characterized by chronic generalized pain in
addition to different symptoms such as fatigue, sleep disturbances, stiffness, cognitive …

This review summarizes the present and emerging knowledge base on the pathophysiology,
diagnosis, and management of fibromyalgia. Epidemiology: Fibromyalgia is the most …

Fibromyalgia (FM) is characterized by chronic widespread pain, unrefreshing sleep, physical
exhaustion, and cognitive difficulties. It occurs in all populations throughout the world, with …

Fibromyalgia is a chronic pain condition present in 2–4% of the population. Fibromyalgia
consists of widespread pain with similarities to neuropathic pain in clinical findings …

Characterised by chronic widespread musculoskeletal pain, generalised hyperalgesia, and
psychological distress, fibromyalgia (FM) is a significant unmet clinical need. The …

Fibromyalgia syndrome is a chronic pain disorder and defies definitively efficacious therapy.
In this review, we summarize the results from the early treatment research as well as recent …

Duloxetine (DLX), milnacipran (MLN), and pregabalin (PGB) are the only drugs licensed by
the US Food and Drug Administration (FDA) for fibromyalgia syndrome (FMS). Evidence on …

Fibromyalgia syndrome (FMS) is a chronic condition with unknown aetiology. The
pathophysiology of the disease is incompletely understood; despite advances in our …